To assess the pharmacokinetics, safety, and tolerability of AZD8233 in participants with Chronic Kidney Disease (CKD), end stage renal disease (ESRD) and healthy participants.

Trial Identifier: D7990C00007
Sponsor: AstraZeneca
PAREXEL International
NCTID:: NCT05065463
Start Date: August 2022
Primary Completion Date: November 2022
Study Completion Date: November 2022

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Polish Translation

Trial Locations

Country Location
PL Gdańsk, PL, 80-952
PL Gliwice, PL, 44-100
PL Łódź, PL, 92-213